###### Strengths and limitations of this study

-   Network meta-analysis together with sensitivity analysis, contradiction analysis and publication bias analysis will evaluate the efficacies of multiple antidiabetic drugs.

-   This study will provide evidence for clinical decision-makers to formulate better treatment of type 2 diabetes.

-   This study is inherently retrospective and based on the published randomised controlled trails only.

Introduction {#s1}
============

Glycaemic control would prevent microvascular and macrovascular complications of type 2 diabetes.[@R1] [@R2] Several categories of oral antidiabetic drugs including biguanides, thiazolidinediones, sulfonylureas, meglitinides, DPP-4 (dipeptidyl peptidase-4) inhibitors and α-glucosidase inhibitors are available for monotherapy of type 2 diabetes. Efficacies of these drugs should be monitored for post-marketing evaluation and for updating of clinical guidelines. However, the latest National Institute for Health and Care Excellence (NICE) guidelines[@R3] [@R4] for treating type 2 diabetes only included those randomised control trials (RCTs) and their meta-analyses published before 2010.

Even if the clinical guidelines were up to date, there are still gaps to be filled among the current pieces of evidence for the glycaemic control efficacy of oral antidiabetic drugs. First, the current evidence for oral antidiabetic drug efficacies was only limited to a number of head-to-head RCTs and meta-analyses, including the most comprehensive study by the Agency for Healthcare Research and Quality,[@R5] and does not cover all possible comparisons among individual drugs. In this situation, network meta-analysis (NMA) that can integrate the evidence from direct and indirect comparisons[@R6] would be applicable. Second, efficacy ranking of the oral antidiabetic drugs was still unknown. The drug recommendation by clinical guidelines was not based on comprehensive and systematic studies for comparing multiple drugs. This gap also suggests an imminent need for NAM that can rank all evaluated interventions.[@R7]

While NAM was used in comparing the efficacies of oral antidiabetic drugs, the available network meta-analyses[@R8] evaluated only treatments combined with metformin. The monotherapy efficacies of individual drugs have not been studied by NAM.

This study conducted a Bayesian NAM[@R5] [@R11] to compare the glycaemic control efficacy of popular oral antidiabetic drugs, including metformin, glimepiride, glyburide, glipizide, repaglinide, nateglinide, sitagliptin, vildagliptin, saxagliptin and SGLT-2 (sodium-glucose transporter-2) inhibitors.

Objective {#s2}
=========

The objective of this study is to compare efficacies of popular antidiabetic drugs by Bayesian NAM on RCTs.

Methods and analysis {#s3}
====================

Design {#s3a}
------

Systematic review and Bayesian NAM.

Information sources {#s3b}
-------------------

Clinical trial reports will be searched from PubMed and Cochrane Library.

Search strategies {#s3c}
-----------------

Drug names, synonyms of type 2 diabetes (eg, type 2 diabetes, type II diabetes and non-insulin-dependent diabetes) and "random\*" will be used as keywords to search titles or abstracts for eligible RCTs from major databases including PubMed, Cochrane Library, ScienceDirect and EMBASE, as well as Food and Drug Administration medical reviews and clinicaltrials.gov website. The search is scheduled between August and October in 2014. For example, the following search strategy will be used in searching PubMed: metformintype 2 diabetesrandom\*1 in title or abstract2 in title or abstract3 in title or abstract4 and 5 and 6

Eligibility criteria {#s3d}
--------------------

The retrieved reports will be screened according to the checklist of eligibility (see online supplementary appendix 1) and the eligibility criteria shown below including participants, interventions, controls, types of study and other criteria.

### Participants {#s3d1}

*Inclusion*: The participants must be adults, aged at least 18 years, suffering from and requiring treatment for type 2 diabetes. *Exclusion*: The participants suffering from other diabetic disease conditions or aged under 18 years.

### Interventions {#s3d2}

*Inclusion*: Any RCT that evaluates the efficacy of these drugs. *Exclusion*: Any RCT that evaluates other drugs or combined treatments of multiple drugs or placebo.

### Controls {#s3d3}

*Inclusion*: Any RCT that evaluates the efficacy of these drugs other than the drug of intervention or placebo. *Exclusion*: Any RCT that evaluates other drugs or combined treatments of multiple drugs.

### Types of study {#s3d4}

*Inclusion*: Only RCTs will be included. *Exclusion*: Observational cohort and case--control studies, case reports, experimental studies and reviews will be excluded.

### Other criteria {#s3d5}

Other inclusion criteria: The RCTs must report complete efficacy data of glycosylated haemoglobin (HbA1c) or fasting blood glucose (FPG) of each treatment. Follow-up periods or durations in RCTs are at least 4 weeks. Other exclusion criteria are (1) duplicated or redundant studies and (2) combined treatments with multiple drugs.

Study selection {#s3e}
---------------

Reviewers will screen all titles or abstracts or full texts for database records independently according to the eligibility criteria. Disagreements between reviewers will be resolved by consensus. Selection process of relevant studies retrieved from databases will be shown in a PRISMA-compliant[@R12] flow chart ([figure 1](#BMJOPEN2014006139F1){ref-type="fig"}).

![Flow chart of the study selection (RCT, randomised controlled trial).](bmjopen2014006139f01){#BMJOPEN2014006139F1}

Data extraction and quality assessment {#s3f}
--------------------------------------

Data of the study characteristics and the clinical outcome measures will be extracted. The data extracted from the RCTs are: (1) authors; (2) publication year; (3) baseline of outcome measures; (4) sample sizes; (5) interventions of both arms; (6) dosages of both arms and (7) treatment outcome measures including HbA1c and FPG. The data will be standardised ([table 1](#BMJOPEN2014006139TB1){ref-type="table"}). The quality of eligible studies will be evaluated according to the Cochrane Collaboration\'s risk of bias tool for assessing risk of bias ([table 2](#BMJOPEN2014006139TB2){ref-type="table"}).[@R13] Radar chart (or star chart)[@R14] will be used to summarise the results.

###### 

Summary of the included RCTs

  Study   Baseline   Sample size   Treatment duration   Drug 1 dosage   Drug 2 dosage   Drug 3 dosage   HbA1c   FPG
  ------- ---------- ------------- -------------------- --------------- --------------- --------------- ------- -----
  RCT 1                                                                                                         
  RCT 2                                                                                                         
  RCT 3                                                                                                         
  RCT 4                                                                                                         
  RCT 5                                                                                                         
  ...                                                                                                           

FPG, fasting blood glucose; HbA1c, glycosylated haemoglobin; RCT, randomised controlled trial.

###### 

Randomised controlled trial (RCT) quality assessment according to the Cochrane Collaboration\'s risk of bias tool

                                           RCT 1   RCT 2   RCT 3   RCT 4   RCT 5   ...
  ---------------------------------------- ------- ------- ------- ------- ------- -----
  Random sequence generation                                                       
  Allocation concealment                                                           
  Blinding of participants and personnel                                           
  Blinding of outcome assessment                                                   
  Incomplete outcome data                                                          
  Selective reporting                                                              
  Other sources of bias                                                            

Each item of included RCT will be evaluated at low risk, unclear risk and high risk of bias, based on the Cochrane Collaboration\'s risk of bias tool.[@R13]

Outcome measures {#s3g}
----------------

Outcome measures of antidiabetic efficacy include mean changes of HbA1c (primary outcome) and FPG (secondary outcome) from baseline and their corresponding variation.

Statistical analysis {#s3h}
--------------------

Pairwise meta-analysis of the included RCTs with random effect model[@R15] [@R16] due to the expected heterogeneity will be conducted. Mean difference (MD) will be used to synthesis the continuous outcome data: mean changes from baseline of the HbA1c (%) and FPG (mol/L) in both arms. I^2^ was used to estimate the heterogeneity.[@R17] Networks will be generated to visualise the results of pairwise meta-analysis and the current evidence from the included RCTs.

NAM based on the Bayesian hierarchical model[@R8] will be performed to compare the efficacy of selected drugs. Placebo will be used as common comparison[@R18] in NMA. Relative MD to the placebo will be output to assess the efficacy. The probability of each drug being ranked in each position based on HbA1c will be computed.[@R19] Kendall's test will be used to test the correlation between the relative MD and the ranking position.

Sensitivity analysis based on the sample size of the RCTs will be conducted when RCTs with sample size less than 50 are excluded. Sensitivity analysis will also be conducted on different baselines. Meta-regression analyses will be conducted on the different follow-up periods and dosages for drugs of the included RCTs. Begg\'s[@R20] and Egger\'s tests[@R21] will be used to evaluate the publication bias. Agreement will be computed to assess the consistency between pairwise and network meta-analyses.

R software[@R22] will be used to implement the analysis workflow. Package "metafor"[@R23] will be used to conduct pairwise meta-analysis. Package 'igraph'[@R24] will be used to visualise the networks. Package 'fmsb'[@R25] will be used to visualise the results of risk of bias assessment. Package 'GeMTC',[@R26] 'R2WinBUGS'[@R27] in R and WinBUGS[@R28] will be used to conduct NAM. Package 'ggplot2'[@R29] will be used to visualise the distribution of ranking probability distribution. p Values lower than 0.05 will be considered statistically significant.

Ethics and dissemination {#s4}
========================

Ethical issues {#s4a}
--------------

No ethical approval is required because this study includes no confidential personal data or interventions with the patients.

Publication plan {#s4b}
----------------

This protocol has been registered (Registration number: CRD42014010567) with the PROSPERO (International Prospective Register of Systematic Reviews).[@R30] The procedures of this systematic review and NAM will be conducted in accordance with the PRISMA-compliant guideline. The results of this systematic review and NAM will be submitted to a peer-reviewed journal for publication.
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